Management tracks: Audentes, Veloxis

Gene therapy company Audentes Therapeutics Inc. (NASDAQ:BOLD) appointed CEO and co-founder Matthew Patterson as chairman. Patterson has been a board member since 2012. Audentes also appointed board member Louis Lange as lead independent director. Lange is a general partner at Asset Management Ventures (Palo Alto, Calif.).

Transplant company Veloxis Pharmaceuticals A/S (CSE:VELO) promoted Ira Duarte to CFO from VP of finance at Veloxis' U.S. subsidiary. She has been interim CFO since Morten Marott stepped down from the position in September...